Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: the effect on fecal flora.
Ciprofloxacin, a new quinolone derivative, was given prophylactically (500 mg twice a day) to 15 patients with acute leukemia during remission induction treatment for a mean duration of 42 days. The effect on the microbial flora of the alimentary tract was evaluated. A rapid elimination of Enterobacteriaceae within three to five days was observed. Bacteroides and Clostridium species were not affected, but the number of anerobic nonsporeforming gram-positive bacilli and anaerobic cocci was decreased. Nine ciprofloxacin-resistant gram-negative rods (Pseudomonas and Acinetobacter species) were isolated but without colonization or subsequent infection. Four of the five bacteriologically documented infections in these patients were caused by gram-positive cocci. Ciprofloxacin was well tolerated, and no side effects were noticed.
Rozenberg-Arska
M
M
Dekker
A W
AW
Verhoef
J
J
D000150:Acinetobacter / Q000187:drug effects / Q000302:isolation & purification; D000208:Acute Disease; D000328:Adult; D001424:Bacterial Infections / Q000517:prevention & control*; D001439:Bacteroides / Q000254:growth & development / Q000302:isolation & purification; D002939:Ciprofloxacin; D003013:Clostridium / Q000254:growth & development / Q000302:isolation & purification; D004064:Digestive System / Q000382:microbiology*; D004352:Drug Resistance, Microbial; D004755:Enterobacteriaceae / Q000187:drug effects / Q000254:growth & development* / Q000302:isolation & purification; D005243:Feces / Q000382:microbiology; D006801:Humans; D007938:Leukemia / Q000150:complications / Q000382:microbiology* / Q000628:therapy; D011549:Pseudomonas / Q000187:drug effects / Q000302:isolation & purification; D011804:Quinolines / Q000494:pharmacology / Q000627:therapeutic use*
D011804:Quinolines; D002939:Ciprofloxacin